Achieve Life Sciences, Inc. (ACHV)

Market Cap	126.90M
Revenue (ttm)	n/a
Net Income (ttm)	-32.94M
Shares Out	34.39M
EPS (ttm)	-1.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	456,983
Open	3.800
Previous Close	3.820
Day's Range	3.600 - 3.960
52-Week Range	3.410 - 5.590
Beta	1.64
Analysts	Strong Buy
Price Target	14.80 (+301.08%)
Earnings Date	Nov 7, 2024

About ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Richard A. Stewart
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHV
• Website: https://www.achievelifesciences.com

Analyst Forecast

According to 5 analysts, the average rating for ACHV stock is "Strong Buy." The 12-month stock price forecast is $14.8, which is an increase of 301.08% from the latest price.

Price Target

$14.8

(301.08% upside)

Analyst Consensus: Strong Buy